A recent study indicates that people who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end conventional lifestyle plans.
Research printed in a prominent health publication points out that while obese people frequently drop about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"People buying these drugs must be aware of the potential of quick rebound weight gain when the therapy is stopped," warns researcher Dr. Susan Jebb.
Such speed of regain suggests a return to starting mass within about one and a half years.
Comparing Treatments
The analysis, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers point out that people who shed pounds through lifestyle changes alone generally have a slower weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Experts suggest the way of the jabs accounts for the heightened regain.
These medications mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement results in hunger is unsuppressed, making overeating far more likely."
A Chronic Condition?
Medical guidelines recommend the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians say that, considering the likelihood of weight regain, the therapy should be considered life-long.
This view is supported by drug manufacturers, who note that the findings "emphasize the long-term character of obesity," akin to managing conditions like hypertension.
Patient Experiences
Users who have discontinued the jabs explain a sudden return of cravings.
"I experienced a switch that goes on and I was suddenly ravenous," recalled one woman.
This difficulty is worsened if patients have not adopted permanent lifestyle or habit changes during treatment.
Significant Adoption
Figures show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Use is higher among women compared to males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers stress that while these medications are effective tools for weight loss, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural management.
